secwatch.observer — SEC 8-K summary
======================================

Issuer:     LianBio (LIANY)
CIK:        0001831283
Form:       8-K
Filed at:   2023-10-30T23:59:59+00:00
Accession:  0001831283-23-000117
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 1.02, 2.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

LianBio terminates mavacamten license for $350M; TP-03 Phase 3 shows mixed results
--------------------------------------------------------------------------------

- Terminated mavacamten license with BMS/MyoKardia; receives $350M payment and released from $127.5M in milestones.
- Phase 3 LIBRA trial met co-primary endpoint of mite eradication (p<0.001) but missed collarette cure (p=0.15).
- Plans to discuss TP-03 results with NMPA and expects to file NDA for Demodex blepharitis in China.
- Pro forma cash and equivalents rise to $444M (from $104M) after termination payment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831283/000183128323000117/0001831283-23-000117-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831283/000183128323000117/lian-20231024.htm
  HTML page:      https://secwatch.observer/filing/0001831283-23-000117

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer